Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Alexion Pharmaceuticals, Inc. · 2025
ClinicalTrials.gov · Datasets · License: Public Domain · 2025
Open Source ↗
amrkidney-transplantation
antibody-mediated rejection, kidney transplantation, biopsy-proven histologic scores, amr, alxn2030, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 885502
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.